BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16690141)

  • 1. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins.
    Baleja JD; Cherry JJ; Liu Z; Gao H; Nicklaus MC; Voigt JH; Chen JJ; Androphy EJ
    Antiviral Res; 2006 Oct; 72(1):49-59. PubMed ID: 16690141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein.
    Beerheide W; Bernard HU; Tan YJ; Ganesan A; Rice WG; Ting AE
    J Natl Cancer Inst; 1999 Jul; 91(14):1211-20. PubMed ID: 10413422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function.
    Cherry JJ; Rietz A; Malinkevich A; Liu Y; Xie M; Bartolowits M; Davisson VJ; Baleja JD; Androphy EJ
    PLoS One; 2013; 8(12):e84506. PubMed ID: 24376816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of High-Risk Papillomavirus 31 E6 Oncogenic Protein and Characterization of E6/E6AP/p53 Complex Formation.
    Conrady MC; Suarez I; Gogl G; Frecot DI; Bonhoure A; Kostmann C; Cousido-Siah A; Mitschler A; Lim J; Masson M; Iftner T; Stubenrauch F; Travé G; Simon C
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
    Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
    Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of papillomavirus E6 proteins with either MAML1 or E6AP clusters E6 proteins by structure, function, and evolutionary relatedness.
    Brimer N; Drews CM; Vande Pol SB
    PLoS Pathog; 2017 Dec; 13(12):e1006781. PubMed ID: 29281732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance.
    Zanier K; Charbonnier S; Baltzinger M; Nominé Y; Altschuh D; Travé G
    J Mol Biol; 2005 Jun; 349(2):401-12. PubMed ID: 15890204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of the human papillomavirus-16 E6 oncoprotein by organic disulfides.
    Beerheide W; Sim MM; Tan YJ; Bernard HU; Ting AE
    Bioorg Med Chem; 2000 Nov; 8(11):2549-60. PubMed ID: 11092540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
    Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
    PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual Screening for Potential Inhibitors of High-Risk Human Papillomavirus 16 E6 Protein.
    Kumar S; Jena L; Mohod K; Daf S; Varma AK
    Interdiscip Sci; 2015 Jun; 7(2):136-42. PubMed ID: 26199214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel small-molecule inhibitor of the human papillomavirus E6-p53 interaction that reactivates p53 function and blocks cancer cells growth.
    Celegato M; Messa L; Goracci L; Mercorelli B; Bertagnin C; Spyrakis F; Suarez I; Cousido-Siah A; Travé G; Banks L; Cruciani G; Palù G; Loregian A
    Cancer Lett; 2020 Feb; 470():115-125. PubMed ID: 31693922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity.
    Drews CM; Brimer N; Vande Pol SB
    PLoS Pathog; 2020 Jan; 16(1):e1008295. PubMed ID: 31971989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicted alpha-helix/beta-sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7.
    Ullman CG; Haris PI; Galloway DA; Emery VC; Perkins SJ
    Biochem J; 1996 Oct; 319 ( Pt 1)(Pt 1):229-39. PubMed ID: 8870673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in silico appraisal of azoic and disulphide derivatives for anticancer activity against HPV E6 oncoprotein to medicate cervical cancer.
    Choudhury AD; Choudhury MD; Chetia P; Chowdhury A; Talukdar AD
    Comb Chem High Throughput Screen; 2014 Jan; 17(1):38-46. PubMed ID: 24164050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
    Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
    Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structures of a human papillomavirus (HPV) E6 polypeptide bound to MAGUK proteins: mechanisms of targeting tumor suppressors by a high-risk HPV oncoprotein.
    Zhang Y; Dasgupta J; Ma RZ; Banks L; Thomas M; Chen XS
    J Virol; 2007 Apr; 81(7):3618-26. PubMed ID: 17267502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/β-catenin pathway through E6AP-dependent degradation of NHERF1.
    Drews CM; Case S; Vande Pol SB
    PLoS Pathog; 2019 Apr; 15(4):e1007575. PubMed ID: 31002735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and function of the papillomavirus E6 protein and its interacting proteins.
    Liu Y; Baleja JD
    Front Biosci; 2008 Jan; 13():121-34. PubMed ID: 17981532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of human papillomavirus 16 E6 to p53 and E6AP is impaired by monoclonal antibodies directed against the second zinc-binding domain of E6.
    Lagrange M; Charbonnier S; Orfanoudakis G; Robinson P; Zanier K; Masson M; Lutz Y; Trave G; Weiss E; Deryckere F
    J Gen Virol; 2005 Apr; 86(Pt 4):1001-1007. PubMed ID: 15784893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation.
    Crook T; Tidy JA; Vousden KH
    Cell; 1991 Nov; 67(3):547-56. PubMed ID: 1657399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.